Please login to the form below

Not currently logged in
Email:
Password:

patent challenge

This page shows the latest patent challenge news and features for those working in and with pharma, biotech and healthcare.

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire. The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court. ... Roche’s defence of its haemophilia drug Hemlibra against a patent infringement challenge by Shire has been

Latest news

  • Shire claims FDA approval for slow-cooked ADHD drug Shire claims FDA approval for slow-cooked ADHD drug

    Either way the new drug is a boost to Shire's ADHD franchise now that Adderall XR and Intuniv (guanfacine) have lost patent protection in most major markets, and along with ... Vyvanse remains under patent challenge from would-be generic rivals, but so

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck. ... In the meantime Merck is also facing a challenge on its injectable patent from Apotex, which filed a petition with the US

  • China turns down one of two Sovaldi patents China turns down one of two Sovaldi patents

    The challenge to the Chinese patent was filed by the Initiative for Medicines, Access &Knowledge (I-MAK), an advocacy group that is trying to overturn Gilead's intellectual property for Sovaldi ... that are currently reviewing patent applications for the

  • German court overturns patent on Lilly blockbuster Alimta German court overturns patent on Lilly blockbuster Alimta

    The patent challenge was not for the compound patent on pemetrexed disodium - the active ingredient in Alimta - but for a vitamin regimen used alongside the drug that is designed to limit ... The German Court of Appeal upheld a challenge by Actavis of

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to quicker review times, QIDP status also gives an extra five years of patent life for the antibiotic product. ... patent challenge filed in a US court by generic drugmaker Hospira.

More from news
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    Indians scalp cowboys in patent war. An unlikely treaty between global pharma and native Americans. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan strategy.

  • Indians scalp cowboys in patent war

    Indians scalp cowboys in patent war. An unlikely treaty between global pharma and native Americans. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan strategy.

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics